+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are studying pediatric participants aged 4 weeks to less than 12 years with human immunodeficiency virus type 1 HIV-1 infection, weighing under 45 kg. The study focuses on treatment-naive children or those virologically suppressed on stable combination antiretroviral therapy for at least 3 months without treatment failure. The main goals are to evaluate the steady-state pharmacokinetics, safety, and tolerability of doravirine DOR when given with two nucleosidenucleotide reverse transcriptase inhibitors NRTIs or as part of the fixed-dose combination FDC of DORlamivudinetenofovir disoproxil fumarate DOR3TCTDF in children aged 6 to less than 12 years weighing 14 to less than 45 kg. Participants receive oral doravirine doses ranging from 7.2 mg to 100 mg based on weight, combined with two NRTIs according to local guidelines, or the fixed-dose combination DOR3TCTDF, for a treatment period of 96 weeks. Those completing the Week 96 visit may join an extension study to receive doravirine for up to an additional 224 weeks or until commercial availability. The study is open-label and conducted across multiple sites. During the study, participants undergo intensive pharmacokinetic sampling at designated times up to 24 hours postdose to measure doravirine levels in plasma. Researchers also monitor safety outcomes up to 24 weeks and additional secondary outcomes including viral load, CD4 T-cell counts, adverse events, adherence, and palatability of the oral pellets or granules. Assessments continue through Week 96, with close monitoring of viral suppression, drug resistance, and tolerability throughout the study and extension period.

Age: 4Weeks - 11YearsAll GendersPhase 2
26 locations
Z

Actively Recruiting

Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.

Age: 18Years +All GendersPhase 3
1190 locations